| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32df7621cbb177ad0b33476f8d3055ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0816525f1e665863e474a65d81644e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84f4e307c3d530a910727cc7c7ec1daa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1282 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate |
2008-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b1613c76363f0a3bba7c89f55ad414d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f69e3f5a06d04aadcc95c373653c0bce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b5a62bbad3065ef1ab2a336b07a3dd6 |
| publicationDate |
2008-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2008260822-A1 |
| titleOfInvention |
SYNTHESIS OF HUMAN SECRETORY IgA AND IgM AND THE FORMATION OF A MEDICAMENT THEREFROM |
| abstract |
A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and pentameric IgM with secretory component to form a antigen specific dimeric secretory IgA and pentameric secretory IgM therapeutic. The antigen specific dimeric secretory IgA and the pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, liquid or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11718661-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10059777-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I720999-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3587449-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2822969-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013150138-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11208471-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10570194-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017037115-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020089203-A1 |
| priorityDate |
2006-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |